Diagnosis of CeD typically involves serological tests, such as immunoglobulin A anti‐tissue transglutaminase antibody (anti‐tTG‐IgA) and anti‐endomysial antibody (EMA), along with duodenal mucosal biopsy, which serves as the gold standard [8, 9]. The gene discussed is TGM2; the disease is cranioectodermal dysplasia.